During our first virtual roundtable, our panel of seasoned biopharma executives discussed the best practices and “pain points” associated with entering European markets. After that roundtable, several members of our panel convened virtually a number of times to explore certain aspects of European market entry in more detail, with a focus on US-based biopharma companies.
This paper provides an outline summary of the third follow-up session, which was held on June 18, 2020. At that session, panelists discussed:
- Guiding principles for building a biopharma organization in Europe
- Key decisions when entering Europe
- The sequencing and timing of investment decisions
- The sequencing and timing of implementation efforts